Translational Chinese Medicine: A Way for Development of Traditional Chinese Medicine

Xuegang Sun, Donglan Lin, Weikang Wu, Zhiping Lv

.

DOI: 10.4236/cm.2011.24029                

Abstract

Translational Chinese medicine is one of the latest developing fields in traditional Chinese medicine. In this paper, we discuss the “3 w” namely, “what is”, “why to advance”, “how to carry out” and the significance of translational Chinese medicine. To overcome the innate drawbacks of traditional Chinese medicine (TCM), the basic theory of TCM had better be refreshed. The safety and efficacy of classic formulae and therapy experience of TCM should be evaluated based on strict quality control and reaffirmed with evidence based medicine. The significance of translational Chinese medicine is to transform Chinese medicine into a balanced, personalized medicine with sound safety, good efficacy and strict quality control.

Keywords

Translational Medicine, Traditional Chinese Medicine, Quality Control, Efficacy, Safety

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	S. P. Mankoff, C. Brander, S. Ferrone and F. M. Marincola, “Lost in Translation: Obstacles to Translational Medicine,” Journal of Translational Medicine, Vol. 2, No. 1, 2004, pp. 14-18.
[2]	X. G. Sun, Q. Liu, Y. Y. Zhao and Y. Cai, “Confirmation, Falsification, or Hermeneutics?” Journal of Nanjing University of Traditional Chinese Medicine (Social Science Edition), Vol. 8, No. 1, 2007, pp. 30-33.
[3]	J. Xu and Y. Yang, “Traditional Chinese Medicine in the Chinese Health Care System,” Health Policy, Vol. 90, No. 2-3, 2009, pp. 133-139. dx.doi.org/10.1016/j.healthpol.2008.09.003
[4]	B. Wu, M. Liu, H. Liu, W. Li, S. Tan, S. Zhang, et al., “Meta-Analysis of Traditional Chinese Patent Medicine for Ischemic Stroke,” Stroke, Vol. 38, No. 6, 2007, pp. 1973-1979.
[5]	X. G. Sun, “The Negative Influences of Pragmatism on Traditional Chinese Medicine (TCM),” Medicine and Philosophy, Vol. 19, No. 9, 1998, pp. 19-21.
[6]	B. Liu, Y. Zhang, J. Hu, L. He and X. Zhou, “Thinking and Practice of Accelerating Transformation of Traditional Chinese Medicine from Experience Medicine to Evidence-Based Medicine,” Frontier Medical, Vol. 5, No. 2, 2011, pp. 163-170. dx.doi.org/10.1007/s11684-011-0143-9
[7]	R. L. Hauger, V. Risbrough, R. H. Oakley, J. A. Olivares-Reyes and F. M. Dautzenberg, “Role of CRF Receptor Signaling in Stress Vulnerability, Anxiety, and Depression,” Annals of the New York Academy of Sciences, Vol. 1179, No. 2009, pp. 120-143.
[8]	M. W. Saif, F. Lansigan, S. Ruta, L. Lamb, M. Mezes, K. Elligers, et al., “Phase I Study of the Botanical Formulation PHY906 with Capecitabine in Advanced Pancreatic and Other Gastrointestinal Malignancies,” Phytomedicine, Vol. 17, No. 3-4, 2010, pp. 161-169.
[9]	Y. Yen, S. So, M. Rose, M. W. Saif, E. Chu, S. H. Liu, et al., “Phase I/II Study of PHY906/Capecitabine in Advanced Hepatocellular Carcinoma,” Anticancer Research, Vol. 29, No. 10, 2009, pp. 4083-4092.
[10]	X. Huang, F. Qin, H. M. Zhang, H. B. Xiao, L. X. Wang, X. Y. Zhang, et al., “Cardioprotection by Guanxin II in Rats with Acute Myocardial Infarction Is Related to Its Three Compounds,” Journal of Ethnopharmacology, Vol. 121, No. 2, 2009, pp. 268-273. dx.doi.org/10.1016/j.jep.2008.10.029
[11]	R. Tilton, A. A. Paiva, J. Q. Guan, R. Marathe, Z. Jiang, W. van Eyndhoven, et al., “A Comprehensive Platform for Quality Control of Botanical Drugs (Phytomicsqc): A Case Study of Huangqin Tang (HQT) and PHY906,” Chinese Medicine, Vol. 5, 2010, pp. 1-15. dx.doi.org/10.1186/1749-8546-5-30
[12]	Y. Sun, Y. Dong, H. J. Jiang, T. T. Cai, L. Chen, X. Zhou, et al., “Dissection of the Role of Paeoniflorin in the Traditional Chinese Medicinal Formula Si-Ni-San against Contact Dermatitis in Mice,” Life Sciences, Vol. 84, No. 11-12, 2009, pp. 337-344. dx.doi.org/10.1016/j.lfs.2008.12.023
[13]	Y. Wang, X. Huang, F. Qin, P. Ren, Z. Zhu, R. Fan, et al., “A Strategy for Detecting Optimal Ratio of Cardioprotection-Dependent Three Compounds as Quality Control of Guan-Xin-Er-Hao Formula,” Journal of Ethnopharmacology, Vol. 133, No. 2, 2011, pp. 735-742. dx.doi.org/10.1016/j.jep.2010.11.006
[14]	Y. Li, T. Wu, H. Shang and K. Yang, “Strategies for Promoting the Development of Evidence-Based Medicine in China,” Journal of Evidence-Based Medicine, Vol. 2, No. 1, 2009, pp. 47-52. dx.doi.org/10.1111/j.1756-5391.2009.01012.x
[15]	M. U. Naidu, “Promise of Translational Medicine: An Evidence-Based Therapeutics,” Indian Journal of Pharmacology, Vol. 43, No. 2, 2011, pp. 103-104. dx.doi.org/10.4103/0253-7613.77332
[16]	G. K. Merijohn and M. G. Newman, “The Translational Clinical Practice System: A Way to Implement the Evidence-Based Approach in the Dental Office,” Journal of the California Dental Association, Vol. 34, No. 7, 2006, pp. 529-539.
[17]	A. Terzic and S. A. Waldman, “Translational Medicine: Path to Personalized and Public Health,” Biomarkers in Medicine, Vol. 4, No. 6, 2010, pp. 787-790. dx.doi.org/10.2217/bmm.10.101
[18]	M. Wehling, “Translational Medicine: Science or Wishful Thinking?” Journal of Translational Medicine, Vol. 6, No. 3, 2008, pp. 1-3.